NASDAQ: LUMOLumos Pharma Inc Stock
$2.52+0.00 (+0%)
Updated Apr 17, 2024
LUMO Price
$2.52
Fair Value Price
N/A
Market Cap
$20.43M
52 Week Low
$2.41
52 Week High
$4.55
P/E
-0.6x
P/B
0.75x
P/S
12.63x
PEG
N/A
Dividend Yield
N/A
Revenue
$2.05M
Earnings
-$34.03M
Gross Margin
100%
Operating Margin
-1,660.8%
Profit Margin
-1,659.4%
Debt to Equity
0.49
Operating Cash Flow
-$31M
Beta
0.74
Next Earnings
May 1, 2024
Ex-Dividend
N/A
Next Dividend
N/A
LUMO Overview
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how LUMO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
LUMO is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
LUMO is good value based on its book value relative to its share price (0.75x), compared to the US Biotechnology industry average (5.83x)
P/B vs Industry Valuation
LUMO is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more LUMO due diligence checks available for Premium users.
Be the first to know about important LUMO news, forecast changes, insider trades & much more!
LUMO News
Valuation
LUMO fair value
Fair Value of LUMO stock based on Discounted Cash Flow (DCF)
Price
$2.52
Fair Value
-$0.01
Undervalued by
19,563.85%
LUMO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
LUMO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.6x
Industry
15.83x
Market
41.64x
LUMO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.75x
Industry
5.83x
LUMO is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
LUMO's financial health
Profit margin
Revenue
$826.0k
Net Income
-$9.5M
Profit Margin
-1,144.9%
LUMO's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
LUMO's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$40.6M
Liabilities
$13.3M
Debt to equity
0.49
LUMO's short-term assets ($40.04M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
LUMO's short-term assets ($40.04M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
LUMO's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
LUMO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$7.4M
Investing
$6.2M
Financing
$742.0k
LUMO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
LUMO vs Biotech Stocks
Lumos Pharma Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.